{"id":"albuterol-salbutamol-hfa","safety":{"commonSideEffects":[{"rate":"null","effect":"Tremors"},{"rate":"null","effect":"Nervousness"},{"rate":"null","effect":"Headache"},{"rate":"null","effect":"Dizziness"},{"rate":"null","effect":"Palpitations"}]},"_chembl":{"chemblId":"CHEMBL714","moleculeType":"Small molecule","molecularWeight":"239.31"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This medication is a bronchodilator that helps to open up the airways in the lungs, making it easier to breathe. It works by stimulating the beta-2 receptors in the bronchial muscles, causing them to relax and dilate. This results in improved airflow and reduced symptoms of asthma and COPD.","oneSentence":"Albuterol/salbutamol HFA is a short-acting beta-2 adrenergic receptor agonist that works by relaxing bronchial muscles to improve airflow to the lungs.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:00:28.510Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Maintenance and relief of bronchospasm in asthma and chronic obstructive pulmonary disease (COPD)"},{"name":"Prevention of bronchospasm during exercise"}]},"trialDetails":[{"nctId":"NCT06473779","phase":"PHASE3","title":"Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-09-30","conditions":"Severe Asthma","enrollment":326},{"nctId":"NCT01931696","phase":"NA","title":"Clinical Assessment of Acupuncture for the Treatment of Chronic Asthma","status":"COMPLETED","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2013-08","conditions":"Asthma","enrollment":200},{"nctId":"NCT06563102","phase":"PHASE4","title":"Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-09-11","conditions":"Mild Asthma","enrollment":101},{"nctId":"NCT06502366","phase":"PHASE3","title":"A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-07-22","conditions":"Asthma","enrollment":422},{"nctId":"NCT01851642","phase":"","title":"Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs","status":"RECRUITING","sponsor":"University of Florida","startDate":"2007-08-09","conditions":"Alpha-1 Antitrypsin Deficiency, AAT Deficiency, AATD","enrollment":220},{"nctId":"NCT06040268","phase":"PHASE1, PHASE2","title":"Advair HFA in Healthy and HAPE Predisposed Subjects","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2023-12-12","conditions":"Altitude Edema","enrollment":60},{"nctId":"NCT04901715","phase":"EARLY_PHASE1","title":"Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia II: Genotype to Phenotype","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2021-06-10","conditions":"Primary Ciliary Dyskinesia","enrollment":27},{"nctId":"NCT06154304","phase":"PHASE3","title":"BE Study of Albuterol Sulfate Inhalation Aerosol 90 mcg Per Actuation in Patients With Stable Mild Asthma","status":"COMPLETED","sponsor":"Cipla Ltd.","startDate":"2023-12-06","conditions":"Bronchial Asthma","enrollment":120},{"nctId":"NCT06272370","phase":"PHASE4","title":"Individualizing Treatment for Asthma in Primary Care","status":"COMPLETED","sponsor":"DARTNet Institute","startDate":"2024-02-01","conditions":"Asthma, Bronchial Diseases, Respiratory Tract Infections","enrollment":103},{"nctId":"NCT04912596","phase":"NA","title":"Pharmacodynamic Equivalence of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate in Adult Patients With Stable Mild Asthma","status":"RECRUITING","sponsor":"Intech Biopharm Ltd.","startDate":"2022-08-15","conditions":"Mild Asthma","enrollment":148},{"nctId":"NCT06618105","phase":"PHASE3","title":"Bronchoprovocation Study to Demonstrate the Pharmacodynamic Bioequivalence of Albuterol Sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of Albuterol Base/Inh) of Macleods Pharmaceuticals Ltd","status":"NOT_YET_RECRUITING","sponsor":"Macleods Pharmaceuticals Ltd","startDate":"2024-10-15","conditions":"Mild Asthma","enrollment":144},{"nctId":"NCT00070707","phase":"PHASE4","title":"Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-04-03","conditions":"Rhinitis, Allergic, Seasonal, Asthma","enrollment":188},{"nctId":"NCT06139991","phase":"PHASE1","title":"Study to Assess the Pharmacokinetic Bioequivalence of Budesonide and Albuterol With an Alternate Propellant Compared to Current Propellant.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-11-16","conditions":"Heathy Participants","enrollment":66},{"nctId":"NCT01471340","phase":"PHASE4","title":"A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2012-01-09","conditions":"Asthma","enrollment":11744},{"nctId":"NCT02741271","phase":"PHASE3","title":"Study of Efficacy and Long-Term Safety of Mometasone Furoate in Combination With Formoterol Fumarate Versus Mometasone Furoate in Children (5 to 11 Years of Age) With Persistent Asthma (MK-0887A-087)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2016-05-11","conditions":"Asthma","enrollment":181},{"nctId":"NCT00739297","phase":"PHASE1","title":"The Safety and Effectiveness of MK0476 (Montelukast) in Patients With Chronic Asthma (0476-388)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-07","conditions":"Chronic Asthma","enrollment":68},{"nctId":"NCT04803734","phase":"NA","title":"Bioequivalence Between Albuterol Sulfate Inhalation Aerosol 108 mcg Per Actuation and Proair HFA (Albuterol Sulfate) Inhalation Aerosol 90 mcg Per Actuation in Healthy Volunteers Under Fasting Conditions","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2021-03-19","conditions":"Healthy","enrollment":60},{"nctId":"NCT05300087","phase":"NA","title":"Bioequivalence Between Albuterol Sulfate Inhalation Aerosol 108mcg Per Actuation and Proair HFA (Albuterol Sulfate) Inhalation Aerosol 90mcg Per Actuation in Healthy Volunteers Under Fasting Conditions","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2022-02-24","conditions":"Healthy","enrollment":60},{"nctId":"NCT00576069","phase":"","title":"Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10-25","conditions":"Asthma","enrollment":60},{"nctId":"NCT00521222","phase":"NA","title":"Evaluating Long Acting Beta Agonists Used to Treat Asthma Among Those With Either Arg/Arg or Gly/Gly Genotypes","status":"COMPLETED","sponsor":"Columbia University","startDate":"2007-06","conditions":"Asthma","enrollment":90},{"nctId":"NCT00530062","phase":"PHASE4","title":"Comparison of Single-Dose Efficacy of an Albuterol Breath-Actuated Inhaler (Albuterol-HFA-BAI) Versus an Albuterol Metered-Dose Inhaler (Albuterol-HFA-MDI) in Participants With Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2007-07-25","conditions":"Asthma","enrollment":49},{"nctId":"NCT05292976","phase":"PHASE3","title":"Pharmacodynamic Bioequivalence Study of Albuterol Sulfate Inhalation Aerosol, 0.09 mg Albuterol Base/ Inhalation","status":"WITHDRAWN","sponsor":"Aurobindo Pharma Ltd","startDate":"2022-04","conditions":"Bronchial Asthma","enrollment":""},{"nctId":"NCT00308685","phase":"PHASE3","title":"Chronic-Dose Safety and Efficacy Study of Albuterol-HFA-BAI in Pediatric Asthmatics","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2006-06-10","conditions":"Asthma","enrollment":95},{"nctId":"NCT01615874","phase":"PHASE2","title":"Study of the Effect of Mometasone Furoate/Formoterol (MF/F), Montelukast and Beclomethasone Dipropionate (BDP) on Plasma Cortisol Levels of Children 5-11 Years Old With Persistent Asthma (P05574)","status":"WITHDRAWN","sponsor":"Organon and Co","startDate":"2013-01","conditions":"Asthma","enrollment":""},{"nctId":"NCT01056159","phase":"PHASE1","title":"A Cumulative Dose Study to Evaluate the Safety and Efficacy of Albuterol in a Dry Powder Inhaler and an HFA MDI (Hydrofluoroalkane Metered Dose Inhaler)","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2010-01","conditions":"Asthma","enrollment":47},{"nctId":"NCT01899144","phase":"PHASE2","title":"Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-07","conditions":"Asthma","enrollment":61},{"nctId":"NCT05152355","phase":"PHASE4","title":"Clinical Equivalence of Budesonide HFA MDI Versus Budesonide Turbuhaler in Mild to Moderate Chinese Asthma Patients","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2019-04-22","conditions":"Asthma","enrollment":270},{"nctId":"NCT00250341","phase":"PHASE4","title":"Non-invasive Measures of Distal Lung Disease in Asthmatics","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2005-09-30","conditions":"Asthma","enrollment":34},{"nctId":"NCT00054964","phase":"PHASE2","title":"Comparative Effectiveness of a Breath-operated Albuterol Inhaler in Asthma Patients With Poor Inhaler Technique","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2003-03-31","conditions":"Asthma","enrollment":14},{"nctId":"NCT00085774","phase":"PHASE3","title":"Comparison of Two Bronchodilator Inhalers in Adolescents and Adults With Exercise-Induced Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2004-06-30","conditions":"Exercise-induced Bronchospasm","enrollment":24},{"nctId":"NCT02139644","phase":"PHASE3","title":"Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-06","conditions":"Asthma","enrollment":787},{"nctId":"NCT00577655","phase":"PHASE3","title":"Albuterol HFA MDI in Pediatric Participants With Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2007-08","conditions":"Asthma","enrollment":103},{"nctId":"NCT02141854","phase":"PHASE3","title":"Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-06","conditions":"Asthma","enrollment":882},{"nctId":"NCT02031640","phase":"PHASE3","title":"A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-12","conditions":"Asthma","enrollment":1113},{"nctId":"NCT02040779","phase":"PHASE3","title":"A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-12-26","conditions":"Persistent Asthma","enrollment":273},{"nctId":"NCT02126839","phase":"PHASE3","title":"A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler in Pediatric Asthmatics","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-05","conditions":"Asthma","enrollment":186},{"nctId":"NCT01058863","phase":"PHASE2","title":"A Dose-ranging Study to Evaluate Albuterol and Hydrofluoroalkane in Subjects Ages 12 and Older With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2010-02","conditions":"Asthma","enrollment":72},{"nctId":"NCT02040766","phase":"PHASE3","title":"A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-12","conditions":"Asthma","enrollment":628},{"nctId":"NCT02513160","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2015-09-30","conditions":"Persistent Asthma","enrollment":713},{"nctId":"NCT02175771","phase":"PHASE3","title":"Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-07","conditions":"Persistent Asthma","enrollment":758},{"nctId":"NCT04584034","phase":"PHASE4","title":"Bronchodilators for Wheeze in Young Children Presenting to Primary Care: a Randomised, Placebo-controlled, Multicentre, Parallel Group Trial","status":"WITHDRAWN","sponsor":"UMC Utrecht","startDate":"2021-09","conditions":"Wheezing","enrollment":""},{"nctId":"NCT04207840","phase":"PHASE4","title":"Study of Drug Exposure in Systemic Circulation of Primatene Mist by Oral Inhalation, Versus Epinephrine Injection by Intramuscular Injection and ProAir by Oral Inhalation in Healthy Individuals","status":"COMPLETED","sponsor":"Amphastar Pharmaceuticals, Inc.","startDate":"2019-12-09","conditions":"Pharmacokinetics, Epinephrine, Albuterol","enrollment":28},{"nctId":"NCT02024204","phase":"NA","title":"Uncontrolled Lower Respiratory Symptoms in the WTC Survivor Program","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2014-04-09","conditions":"Lung Diseases, Medication Compliance","enrollment":60},{"nctId":"NCT03528577","phase":"PHASE3","title":"A Study to Evaluate the Effect of of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base (Sun Pharmaceuticals Industries Limited)","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2018-09-22","conditions":"Asthma","enrollment":128},{"nctId":"NCT02584257","phase":"PHASE3","title":"Pharmacodynamic Bioequivalence of Metered Dose Inhalers of Albuterol Sulfate in Patients With Stable Mild Asthma","status":"COMPLETED","sponsor":"Lupin, Inc.","startDate":"2016-04","conditions":"Mild Persistent Asthma","enrollment":217},{"nctId":"NCT00557180","phase":"","title":"Examining the Link Between Obesity, Inflammation, and Response to Asthma Medications","status":"COMPLETED","sponsor":"National Jewish Health","startDate":"2007-10","conditions":"Asthma, Obesity","enrollment":33},{"nctId":"NCT01388595","phase":"PHASE4","title":"Fluticasone and Salmeterol in Allergic Rhinitis","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2006-11","conditions":"Allergic Rhinitis","enrollment":23},{"nctId":"NCT02478398","phase":"PHASE3","title":"Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-07-20","conditions":"Rhinitis, Allergic, Seasonal","enrollment":1025},{"nctId":"NCT03364608","phase":"PHASE2","title":"Study to Compare PT007 to Placebo MDI and Open-Label Proventil® HFA in Adult and Adolescent Subjects With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-12-15","conditions":"Asthma","enrollment":86},{"nctId":"NCT03371459","phase":"PHASE2","title":"Assessment of the Safety, Efficacy, PK, and Extrapulmonary Pharmacodynamics (PD) of Albuterol Sulfate Pressurized Inhalation Suspension (Hereafter Referred to as AS MDI) Compared to Proventil as an Active Control in Subjects With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-12-29","conditions":"Asthma","enrollment":46},{"nctId":"NCT01194700","phase":"PHASE4","title":"Comparative Study of Lung Bioavailability of HFA-Seretide Via Current Spacer Devices in Healthy Volunteers","status":"COMPLETED","sponsor":"Brian J Lipworth","startDate":"2009-11","conditions":"Asthma","enrollment":19},{"nctId":"NCT00829257","phase":"PHASE4","title":"Additive Effects of QVAR to (Seretide) on Surrogate Markers of Airway Inflammation in Refractory Asthma","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2009-01","conditions":"Asthma","enrollment":15},{"nctId":"NCT03643874","phase":"PHASE2","title":"Safety and Efficacy of Albuterol Administered by the Halix™ Dry Powder Inhaler in Subjects With Asthma","status":"COMPLETED","sponsor":"Concentrx Pharmaceuticals, Inc.","startDate":"2018-06-30","conditions":"Asthma","enrollment":13},{"nctId":"NCT03373409","phase":"PHASE1","title":"Safety and Pharmacokinetics of Halix(TM) Albuterol Unit Dose Disposable Inhaler Versus Albuterol MDI","status":"COMPLETED","sponsor":"Concentrx Pharmaceuticals, Inc.","startDate":"2017-11-30","conditions":"Asthma","enrollment":12},{"nctId":"NCT02182674","phase":"PHASE2","title":"A Confirmation Study of Combivent HFA Inhalation Aerosol in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2000-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":66},{"nctId":"NCT00394329","phase":"PHASE3","title":"(CARE Network Trial - Treating Children to Prevent Exacerbations of Asthma (TREXA)","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2006-11","conditions":"Asthma","enrollment":288},{"nctId":"NCT02045953","phase":"PHASE1","title":"A Study to Assess the Systemic Exposure of FLIXOTIDE™ (Fluticasone Propionate) and SERETIDE™ (Fluticasone Propionate and Salmeterol) Given With VENTOLIN™ Mini-Spacer Compared to the Aerochamber Plus Spacer","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-01-29","conditions":"Asthma","enrollment":21},{"nctId":"NCT03549897","phase":"PHASE3","title":"Bronchoprovocation Study to Evaluate the Pharmacodynamics of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base","status":"UNKNOWN","sponsor":"Amneal Ireland Limited","startDate":"2018-03-16","conditions":"Asthma","enrollment":100},{"nctId":"NCT01576718","phase":"PHASE2","title":"A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2012-04","conditions":"Asthma","enrollment":889},{"nctId":"NCT03480997","phase":"PHASE1","title":"Acute Bronchodilator Effect of Inhaled Albuterol Sulfate and Ipratropium Bromide in Patients With Stable COPD","status":"COMPLETED","sponsor":"Pneuma Respiratory, Inc","startDate":"2016-12-27","conditions":"COPD","enrollment":46},{"nctId":"NCT01252758","phase":"PHASE2","title":"Dose Finding Study of Albuterol Sulfate in Patients With Intermittent or Persistent Mild Asthma","status":"WITHDRAWN","sponsor":"Acerus Pharmaceuticals Corporation","startDate":"2012-11","conditions":"Asthma","enrollment":""},{"nctId":"NCT00200967","phase":"PHASE3","title":"Asthma Clinical Research Network (ACRN) Trial - Long-Acting Beta Agonist Response by Genotype (LARGE)","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2004-12","conditions":"Asthma","enrollment":87},{"nctId":"NCT01189396","phase":"PHASE2","title":"Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006","status":"COMPLETED","sponsor":"Amphastar Pharmaceuticals, Inc.","startDate":"2010-07","conditions":"Asthma, Bronchospasm, Chronic Obstructive Pulmonary Disease (COPD)","enrollment":27},{"nctId":"NCT01772368","phase":"PHASE2","title":"Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-01","conditions":"Asthma","enrollment":72},{"nctId":"NCT01479621","phase":"PHASE2","title":"A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2012-01","conditions":"Asthma","enrollment":909},{"nctId":"NCT00528723","phase":"PHASE3","title":"Efficacy and Tolerability of Beclomethasone Plus Salbutamol in HFA pMDI Fixed Combination vs Beclomethasone Plus Salbutamol in CFC pMDI Fixed Combination in a 12-week Treatment Period of Adult Patients With Uncontrolled Asthma","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2007-11","conditions":"Bronchial Asthma","enrollment":180},{"nctId":"NCT01344655","phase":"PHASE4","title":"Study to Investigate the Effect of Formoterol vs Salmeterol on Small Airways Physiological Parameters in COPD Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2011-04","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":16},{"nctId":"NCT01584492","phase":"PHASE2","title":"Bronchodilator Effect of CHF1535 pMDI Versus Free Combination of Beclometasone Plus Formoterol pMDI in Asthmatic Children","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2011-12","conditions":"Asthma","enrollment":59},{"nctId":"NCT00384189","phase":"PHASE3","title":"A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children (6-11 Years) With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-09","conditions":"Asthma","enrollment":1080},{"nctId":"NCT00441441","phase":"PHASE3","title":"A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-02","conditions":"Asthma","enrollment":351},{"nctId":"NCT00400608","phase":"PHASE4","title":"A Study In Pediatric Subjects With Asthma Using ADVAIR HFA, ADVAIR HFA With Spacer, And ADVAIR DISKUS","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-10","conditions":"Asthma","enrollment":28},{"nctId":"NCT00144846","phase":"PHASE3","title":"Inhaled Albuterol Sulfate For Acute Wheezing Due To Obstructive Airways Disease In Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-09","conditions":"Asthma","enrollment":80},{"nctId":"NCT02466347","phase":"PHASE1","title":"Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers Without Charcoal Block","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2014-06","conditions":"Asthma, Chronic Obstructive Pulmonary Disease (COPD)","enrollment":45},{"nctId":"NCT02150499","phase":"PHASE3","title":"A Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects","status":"TERMINATED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2014-07","conditions":"Asthma","enrollment":18},{"nctId":"NCT02466503","phase":"PHASE1","title":"Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers With Charcoal Block","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2014-08","conditions":"Asthma, Chronic Obstructive Pulmonary Disease (COPD)","enrollment":45},{"nctId":"NCT02162784","phase":"PHASE2","title":"Efficacy Study of SYN006 HFA MDI in Asthma Patients","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2013-02","conditions":"Asthma","enrollment":39},{"nctId":"NCT01763463","phase":"","title":"WEUSKOP6416: Evaluating Pneumonia in Chronic Obstructive Pulmonary Disease (COPD) Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1},{"nctId":"NCT01019694","phase":"PHASE3","title":"Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":470},{"nctId":"NCT00809757","phase":"PHASE3","title":"A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2008-12","conditions":"Asthma","enrollment":197},{"nctId":"NCT02173678","phase":"PHASE1","title":"Safety and Tolerability of COMBIVENT® HFA as Compared to COMBIVENT® CFC and Placebo HFA in Healthy Male and Female Subjects","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1999-10","conditions":"Healthy","enrollment":12},{"nctId":"NCT00818454","phase":"PHASE2","title":"4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-12","conditions":"Asthma","enrollment":226},{"nctId":"NCT01490125","phase":"PHASE3","title":"The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":247},{"nctId":"NCT01844401","phase":"PHASE1","title":"Pharmacokinetic and Pharmacodynamic Profiles of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients With Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-04","conditions":"Asthma","enrollment":15},{"nctId":"NCT00909779","phase":"PHASE3","title":"Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2009-06","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":841},{"nctId":"NCT00096616","phase":"PHASE2","title":"Combivent® CFC Metered Dose Inhaler (MDI) in Moderate to Severe Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2004-11","conditions":"Asthma","enrollment":113},{"nctId":"NCT01795664","phase":"PHASE3","title":"Compare the Effects of Seretide® Evohaler and a Generic Salmeterol/Fluticasone Hydrofluoroalkane (HFA) Pressurized Metered-dose Inhaler (pMDI) on Functional Respiratory Imaging Parameters in Asthmatic Patients","status":"COMPLETED","sponsor":"FLUIDDA nv","startDate":"2013-03","conditions":"Asthma","enrollment":16},{"nctId":"NCT00635505","phase":"PHASE3","title":"Controlled, 12-Week Study of Albuterol HFA Versus the Active Control, Proventil(R)-HFA in Asthmatic Patients","status":"TERMINATED","sponsor":"Amphastar Pharmaceuticals, Inc.","startDate":"2007-09","conditions":"Asthma","enrollment":300},{"nctId":"NCT00634517","phase":"PHASE3","title":"4-Week Study of Efficacy, Safety and PK of Albuterol-HFA Versus Proventil-HFA in Pediatric Asthma","status":"TERMINATED","sponsor":"Amphastar Pharmaceuticals, Inc.","startDate":"2008-03","conditions":"Asthma","enrollment":48},{"nctId":"NCT00634829","phase":"PHASE3","title":"Single-Dose Cross-Over Study of the Effects of Albuterol-HFA in Exercise Induced Bronchoconstriction","status":"TERMINATED","sponsor":"Amphastar Pharmaceuticals, Inc.","startDate":"2008-02","conditions":"Asthma, Bronchospasm","enrollment":24},{"nctId":"NCT01302587","phase":"","title":"A Study to Evaluate the Integrated Dose Counter on an Albuterol Hydrofluoroalkane (HFA) Metered Dose Inhaler (MDI)","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2011-03","conditions":"Asthma, Chronic Obstructive Pulmonary Disease (COPD), Emphysema","enrollment":306},{"nctId":"NCT00583986","phase":"PHASE3","title":"Reliability of a Top Mount Actuation Indicator With Levalbuterol MDI in Adult and Pediatric Subjects With Asthma or COPD","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2005-09","conditions":"Asthma, Chronic Obstructive Pulmonary Disease, COPD","enrollment":150},{"nctId":"NCT00685347","phase":"PHASE2","title":"Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol in Pediatric Subjects","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2003-01","conditions":"Asthma, Bronchoconstriction","enrollment":33},{"nctId":"NCT00684866","phase":"PHASE2","title":"Safety and Tolerability Study of Levalbuterol HFA and Racemic Albuterol HFA in Pediatrics Subjects With Asthma","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2003-01","conditions":"Asthma","enrollment":31},{"nctId":"NCT00685022","phase":"PHASE2","title":"Safety and Tolerability Study of Levalbuterol HFA Compared to Racemic Albuterol HFA in Subjects With Asthma","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2003-06","conditions":"Asthma","enrollment":49},{"nctId":"NCT00684827","phase":"PHASE2","title":"A Safety and Tolerability Study of Levalbuterol HFA Metered Dose Inhaler in Subjects With Asthma","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2002-10","conditions":"Asthma","enrollment":32},{"nctId":"NCT00064389","phase":"PHASE3","title":"Long Term Safety Study of Levalbuterol and Racemic Albuterol in Subjects Twelve Years of Age and Older With Asthma","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2003-01","conditions":"Asthma","enrollment":746},{"nctId":"NCT00268723","phase":"PHASE3","title":"Efficacy Study of Single-Dose Levalbuterol Tartrate HFA MDI Vs Placebo in Subjects 18 Years and Older With EIB","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2005-12","conditions":"Exercise-induced Bronchospasm","enrollment":15},{"nctId":"NCT00073840","phase":"PHASE3","title":"Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2002-12","conditions":"Asthma","enrollment":386},{"nctId":"NCT00685425","phase":"PHASE3","title":"Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2002-10","conditions":"Asthma, Bronchoconstriction","enrollment":62},{"nctId":"NCT00646009","phase":"PHASE3","title":"Symbicort Onset of Action 2","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-03","conditions":"Asthma","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ProAir HFA","short-acting β2-adrenergic agonists"],"phase":"phase_3","status":"active","brandName":"albuterol/salbutamol HFA","genericName":"albuterol/salbutamol HFA","companyName":"Teva Branded Pharmaceutical Products R&D, Inc.","companyId":"teva-branded-pharmaceutical-products-r-d-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Albuterol/salbutamol HFA is a short-acting beta-2 adrenergic receptor agonist that works by relaxing bronchial muscles to improve airflow to the lungs. Used for Maintenance and relief of bronchospasm in asthma and chronic obstructive pulmonary disease (COPD), Prevention of bronchospasm during exercise.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}